Health & Safety Industry Today

Low-Grade Glioma Market is Predicted to Exhibit Remarkable Growth | Novartis, Day One Biopharmaceuticals, Beigene, Hoffmann-La Roche, Incyte, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight's "Low-grade glioma Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Low-grade glioma, historical and forecasted epidemiology as well as the Low-grade glioma market trends in the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom and Japan.
Published 28 December 2023

{Delhi, India} To strategically aid Low-Grade Glioma companies developing drugs for Low-Grade Glioma, DelveInsight launched a report titled as “Low-Grade Glioma Market Insight, Epidemiology And Market Forecast - 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Low-Grade Glioma market.

Get a free sample of “Low-Grade Glioma Market Size, Share, & Forecast Report”: 

Key Highlights from Low-Grade Glioma market Report:

  • The Low-Grade Glioma market size was valued approximately USD 969 million in 2021 and is anticipated to grow with a significant CAGR of 3.4% during the study period (2019-2032)
  • In the Seven Major Markets (7MM), the overall incident population affected by Low-Grade Glioma amounted to 9,078 cases, and these numbers are projected to increase over the study duration spanning from 2019 to 2032.
  • Key Low-Grade Glioma Companies: Day One Biopharmaceuticals, Servier, AnHeart Therapeutics, SpringWorks Therapeutics, Day One Biopharmaceuticals, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
  • Key Low-Grade Glioma Therapies: DAY101, Vorasidenib, AB-218, Mirdametinib, Tovorafenib (DAY101), BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
  • The Low-Grade Glioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Low-Grade Glioma pipeline products will significantly revolutionize the Low-Grade Glioma market dynamics.

Low-Grade Glioma Country based Treatment Overview: 

Currently, there are no approved pharmaceutical drugs specifically designed for treating Low-grade glioma (LGG). Typically, the management of LGG involves a multifaceted approach comprising surgery, careful monitoring, and radiation therapy. In cases where the tumor's location allows for safe removal, a neurosurgeon will aim to surgically excise as much of the tumor as feasible.

Low-grade glioma (LGG) is a type of brain tumor that originates from glial cells in the brain. Glial cells provide support and protection for neurons in the nervous system. These tumors are considered "low-grade" due to their slower growth rate and less aggressive nature compared to high-grade gliomas.

To Know in detail about the Low-Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low-Grade Glioma Market Forecast

Low-Grade Glioma Epidemiology Insights: 

The Low-Grade Glioma epidemiological data in the report includes historical and projected figures concerning primary brain cancer, specifically low-grade glioma. It encompasses total incidents, grade-specific occurrences, age-based occurrences, type-specific cases, and further divisions based on molecular alterations, as well as distinguishing between enhancing and non-enhancing low-grade glioma cases.

In a study conducted by Greuter et al. (2021), findings revealed that about 74% of Low-Grade Gliomas (LGGs) diagnosed in children are classified as WHO Grade I, whereas 26% are categorized as Grade II. Conversely, in adults, there is a reverse trend, where approximately 85–90% of LGG cases fall under WHO Grade II, with 10–15% identified as Grade I. The study highlighted that among children, the majority of LGGs are identified as pilocytic astrocytoma (around 65%), whereas in adults, diffuse LGG (constituting 60%) is more prevalent. To estimate future trends, the contribution of Grade I and II cases was derived from the CBTRUS data report of 2021.

In 2022, the total number of newly reported cases of LGG in the United States stands at approximately 4,000. The United States holds the highest share of incident cases of LGG, contributing to around 40% of the total incident population among the Seven Major Markets (7MM) during the same period.

Low-Grade Glioma Epidemiology Segmentation:

The Low-Grade Glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Low-Grade Glioma
  • Prevalent Cases of Low-Grade Glioma by severity
  • Gender-specific Prevalence of Low-Grade Glioma
  • Diagnosed Cases of Episodic and Chronic Low-Grade Glioma

Download the report to understand which factors are driving Low-Grade Glioma epidemiology trends @ Low-Grade Glioma Epidemiology Forecast

Low-Grade Glioma Therapies and Key Companies

  • DAY101: Day One Biopharmaceuticals
  • Vorasidenib: Servier
  • AB-218: AnHeart Therapeutics
  • Mirdametinib: SpringWorks Therapeutics
  • Tovorafenib (DAY101): Day One Biopharmaceuticals
  • BGB-290: Beigene
  • Infigratinib: Helsinn
  • FT-2102 (Olutasidenib): Forma Therapeutics
  • Vinblastine + Bevacizumab: Hoffmann-La Roche

Emerging Low-Grade Glioma drugs Uptake:

The drug section within the Low-grade glioma report provides an in-depth analysis of the mid and late-stage pipeline drugs dedicated to Low-grade glioma. This segment assists in comprehending the clinical trial specifics, pharmacological actions, collaborations, agreements, approval status, patent particulars, along with the latest news and press releases related to each drug included in the report.

In March 2023, The FDA in the United States granted approval to TAFINLAR in combination with MEKINIST (manufactured by Novartis) for pediatric patients aged 1 year and above diagnosed with low-grade glioma (LGG) having a BRAF V600E mutation necessitating systemic therapy.

In June 2022, Day One Biopharmaceuticals released encouraging initial findings from the pivotal Phase II (FIREFLY-1) trial showcasing favorable outcomes using tovorafenib (DAY101) among children experiencing relapsed low-grade glioma (pLGG).

At the American Society of Clinical Oncology (ASCO) 2022, Novartis disclosed Phase II findings concerning a novel oral targeted therapy combination (Dabrafenib/Trametinib).

Discover more about therapies set to grab major Low-Grade Glioma market share @ Low-Grade Glioma Treatment Landscape

Low-Grade Glioma Market Forecast:

Currently, the treatment options approved for Low-grade glioma are absent, resulting in a significant unmet need for therapies that can impede its progression. The understanding of Low-grade glioma's pathophysiology remains limited. However, the Low-grade glioma sector is expected to become increasingly lucrative shortly, thanks to the anticipated expansion of available treatment alternatives and advancements in early tumor detection for this grade.

The anticipated introduction of prospective treatments such as Day One Biopharmaceuticals' DAY101, AnHeart Therapeutic's AB218, SpringWorks Therapeutics' mirdametinib, Servier's vorasidenib (AG-881), and various other therapies is poised to potentially expand the market size in the forthcoming years. 

Scope of the Low-Grade Glioma Market Report:

  • Geography Coverage: 7MM
  • Study Period: 2019-2032
  • Low-Grade Glioma Market Size: ~USD 969 million in 2021
  • Key Low-Grade Glioma Companies: Novartis, Day One Biopharmaceuticals, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Servier, Helsinn, Forma Therapeutics, Hoffmann-La Roche, Incyte, Eli Lilly, and Company, and others

To know more about Low-Grade Glioma companies working in the treatment market, visit @ Low-Grade Glioma Clinical Trials and Therapeutic Assessment

Related Reports: 

Low-Grade Glioma Epidemiology 

DelveInsight's 'Low-Grade Glioma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Low-Grade Glioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432, Las Vegas

State:  Nevada (89107)

Country: United States

Website: https://www.delveinsight.com/consulting 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Other Industry News

Ready to start publishing

Sign Up today!